MODERNIZE 1: Siplizumab as Induction Therapy in Renal Transplant Recipients
MODERNIZE Siplizumab
Sponsor: Nefro Avillion Clinical Development, LLC
Enrolling: Male and Female Patients
IRB Number: ACYY1906
U.S. Govt. ID: NCT07508787
Contact: Transplant Clinical Research Center: 212-305-3839 / tcrcstudyreferral@cumc.columbia.edu
Additional Study Information: The goal of this clinical trial is to learn if an investigational medication called siplizumab can prevent rejection of a kidney transplant patients with end stage kidney disease. The study will compare two different doses of siplizumab to a medication that is standardly used post kidney transplant to prevent rejection, rabbit anti-thymocyte globulin (rATG). Participants will be followed for 1 year post transplant.
This study is closed
Investigator
Joshua Weiner, MD
Do You Qualify?
Are you between 18 and 70 years old? Yes No
Are you on the kidney transplant waiting list? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Transplant Clinical Research Center
tcrcstudyreferral@cumc.columbia.edu
212-305-3839